{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:04:47Z","timestamp":1792062287687,"version":"4.4.0"},"reference-count":57,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology","award":["2023ZD0507700"],"award-info":[{"award-number":["2023ZD0507700"]}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371317"],"award-info":[{"award-number":["32371317"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473761 and 22277110"],"award-info":[{"award-number":["82473761 and 22277110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["242301420005"],"award-info":[{"award-number":["242301420005"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research Project for Basic Research in Henan Province Universities","award":["25ZX001"],"award-info":[{"award-number":["25ZX001"]}]},{"name":"Open Research Fund of Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education","award":["FMUGIC-202401"],"award-info":[{"award-number":["FMUGIC-202401"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/13543776.2025.2468792","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T13:03:21Z","timestamp":1739797401000},"page":"493-501","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["JBI-802: the first orally available LSD1\/HDAC6 dual inhibitor to enter clinical trials"],"prefix":"10.1080","volume":"35","author":[{"given":"Jingya","family":"Zhang","sequence":"first","affiliation":[{"name":"Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangli","family":"Ren","sequence":"additional","affiliation":[{"name":"Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Song","sequence":"additional","affiliation":[{"name":"Zhengzhou University","place":["Zhengzhou, China"]},{"name":"Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[{"name":"Zhengzhou University","place":["Zhengzhou, China"]},{"name":"Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01341-7"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/0113895575320344240625080555"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.013"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666211108105214"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.12.012"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.08.027"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23123194"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2017-0068"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106443"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.114042"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0811-9"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-18611-0.00029-2"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.10.019"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.09.022"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2021-0326"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02133"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14366"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj20021321"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105274"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574892815666200217125419"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01782"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-022-00704-6"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw522"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114920"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42237-3"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.052"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127763"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279063"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14236014"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00966"},{"key":"e_1_3_4_33_1","unstructured":"Jubilant Therapeutics Inc. Cyclopropyl-amide compounds as DUALLSD1\/HDAC inhibitors. WO2017195216A1. 2017."},{"key":"e_1_3_4_34_1","unstructured":"Jubilant Therapeutics Inc. DUAL LSD1\/HDAC INHIBITORS. WO2023\/170715A1. 2023."},{"key":"e_1_3_4_35_1","volume-title":"American Association of Cancer Research Annual meeting","author":"D S","year":"2020","unstructured":"D S, Rajagopal S, Sadhu N, et al. JBI-802: novel LSD1\/HDAC6 inhibitor with a unique mechanism of action. In: American Association of Cancer Research Annual meeting; Washington, United States; 2020."},{"key":"e_1_3_4_36_1","volume-title":"American Association of Cancer Research Annual meeting","author":"Sivanandhan Sr D","year":"2020","unstructured":"Sivanandhan Sr D, Nair S, Basavaprabhu B, et al. Novel dual small molecule inhibitor targeting LSD1 and HDAC6. In: American Association of Cancer Research Annual meeting; Washington, United States; 2020."},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-1756"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.CancEpi22-B029"},{"key":"e_1_3_4_39_1","volume-title":"American Association of Cancer Research Annual Meeting","author":"Dhanalakshmi S","year":"2019","unstructured":"Dhanalakshmi S, Rajagopal R, Nair S, et al. Novel dual small molecule inhibitor targeting LSD1 and HDAC6\/8. American Association of Cancer Research Annual Meeting; 2019 March 29 - April 03; Atlanta, Georgia. 2019. [cited 2025 Feb 19]. https:\/\/www.jubilantbiosys.com\/wp-content\/uploads\/2019\/09\/Novel-Dual-Small-Molecule-Inhibitor-Targeting-LSD1-and-HDAC6-8.pdf"},{"key":"e_1_3_4_40_1","unstructured":"A first-in-human open-label dose escalation and expansion study of orally administered jbi-802 in patients with advanced solid tumors. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05268666"},{"key":"e_1_3_4_41_1","unstructured":"Jubilant Therapeutics Inc. Receives orphan drug designation for JBI-802 for acute myeloid leukemia (AML) and small cell lung cancer (SCLC). 2023. Available from: http:\/\/bit.ly\/3H5xF7q"},{"key":"e_1_3_4_42_1","unstructured":"JBI-802 initial Phase I data suggests therapeutic potential in sensitizing immunotherapy resistant tumors and in Myeloproliferative Neoplasms with thrombocytosis. 2024. Available from: https:\/\/www.prnewswire.com\/news-releases"},{"key":"e_1_3_4_43_1","unstructured":"Phase 1\/Phase 2 study to assess safety and efficacy of orally administered JBI-802 in subjects with myeloproliferative neoplasms (MPN) and myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) with thrombocytosis. 2024. Available from: https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12624000478516"},{"key":"e_1_3_4_44_1","unstructured":"Jubilant Therapeutics Inc. JBI-802 initial Phase I data suggests therapeutic potential in sensitizing immunotherapy resistant tumors and in Myeloproliferative Neoplasms with thrombocytosis. [cited 2025 Feb 19]. https:\/\/www.jubilanttx.com\/pressreleasedetails.aspx?mpgid=1473&pgid=1475&pressid=504"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01607-9"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00633"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja101557k"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-006-0660-8"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01324"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.10.010"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16060891"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.09.003"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00736-3"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116901"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03489-9"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136900"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00449"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00736"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2468792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:16:41Z","timestamp":1746184601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2468792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/13543776.2025.2468792"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2468792","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}